Rheumatology · Medical Literature
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/II Clinical Trial.
Abstract
This Phase Ib/II study aimed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Firsekibart in the treatment of gout flares. Phase Ib part utilized an open-label, single-dose, dose-escalation design. Patients were enrolled and received a single subcutaneous injection of Firsekibart at a dose of 50, 100, or 195 mg. Phase II part was a multicenter, randomized, double-blind, parallel, positive-controlled study. Patients were assigned to receive either Firsekibart (100 or 195 mg) or Diprospan. As of June 9, 2022, a total of 120 patients (Phase Ib N = 29, Phase II N = 91) received the study drugs. In Phase Ib, Firsekibart demonstrated dose-dependent efficacy. Firsekibart 50 mg treatment provided less pain relief compared to the 100 mg and 195 mg. In Phase II, the visual analogue scale (VAS) score decreased by 5.51 ± 1.56, 4.72 ± 1.56 and 4.94 ± 2.44 cm after 72 h in Firsekibart 195 mg, 100 mg and Diprospan groups, respectively. Firsekibart 195 mg treatment showed a more effective pain relief trend. The pharmacokinetic (PK) profile of serum Firsekibart exhibits typical characteristics of monoclonal antibodies, featuring slow absorption (median Tmax approximately 5.9-6.9 days), limited distribution (distributed volume approximately 8.0-12.1 L) and slow elimination (clearance approximately 9.2-11.5 mL/h). Safety of Firsekibart was favorable and comparable across doses and relative to Diprospan. A single subcutaneous injection of Firsekibart is safe and well tolerated in the treatment of gout flares. It provides dose-dependent pain relief with favorable pharmacokinetic properties and potential for reducing the risk of gout flare recurrence. Trial Registration: ClinicalTrials.gov NCT05328531.
Clinical relevance
Gout flares represent one of the most acutely painful rheumatologic conditions, and current anti-inflammatory options — including corticosteroids, NSAIDs, and colchicine — carry significant tolerability limitations, particularly in patients with renal impairment, cardiovascular disease, or gastrointestinal comorbidities. Firsekibart, a novel subcutaneous monoclonal antibody, targets the IL-1 pathway and offers a potential single-dose biologic alternative for acute flare management, addressing an unmet need for durable, well-tolerated therapy. This Phase Ib/II trial provides the first structured clinical pharmacokinetic and efficacy dataset for this agent in gout, making it immediately relevant to rheumatologists managing refractory or high-risk flare patients.
Key findings
1. Dose-dependent efficacy (Phase Ib): Firsekibart 50 mg provided inferior pain relief compared to the 100 mg and 195 mg cohorts in the open-label, single-dose escalation phase (N=29), confirming a clinically meaningful dose-response relationship. 2. VAS pain reduction at 72 hours (Phase II, primary efficacy endpoint): Firsekibart 195 mg achieved a mean VAS reduction of 5.51 ± 1.56 cm, Firsekibart 100 mg achieved 4.72 ± 1.56 cm, and active comparator Diprospan (betamethasone dipropionate) achieved 4.94 ± 2.44 cm — with Firsekibart 195 mg demonstrating the most favorable pain relief trend. 3. Non-inferiority signal vs. corticosteroid: Firsekibart 195 mg VAS reduction numerically exceeded Diprospan at 72 hours (5.51 vs. 4.94 cm), suggesting at least comparable short-term analgesic efficacy to standard corticosteroid therapy, though formal non-inferiority or superiority statistical thresholds were not explicitly reported in the abstract. 4. Pharmacokinetics — absorption: Subcutaneous firsekibart exhibits slow absorption typical of IgG monoclonal antibodies, with a median Tmax of approximately 5.9–6.9 days across dose cohorts. 5. Pharmacokinetics — distribution and elimination: Volume of distribution was limited at approximately 8.0–12.1 L (consistent with predominantly intravascular distribution), and clearance was slow at approximately 9.2–11.5 mL/h, both characteristic of a long-acting monoclonal antibody with potential for sustained IL-1 blockade beyond the acute flare window. 6. Safety profile: Firsekibart demonstrated a favorable and comparable safety and tolerability profile across all dose levels (50, 100, 195 mg) and relative to Diprospan in a combined population of 120 patients, with no dose-limiting safety signals identified as of the June 9, 2022 data cutoff.
Practice implications
Rheumatologists should consider subcutaneous firsekibart 195 mg as a promising single-dose biologic option for acute gout flare management, particularly in patients for whom corticosteroids, NSAIDs, or colchicine are contraindicated or poorly tolerated — given its favorable safety profile comparable to Diprospan and numerically superior VAS reduction at 72 hours. The prolonged half-life and slow elimination kinetics (Tmax ~5.9–6.9 days, low clearance ~9.2–11.5 mL/h) suggest sustained IL-1 inhibition that may reduce early flare recurrence risk, warranting prospective evaluation of recurrence rates as a secondary endpoint in future Phase III trials. Patient selection for this agent should prioritize those with recurrent polyarticular flares, CKD limiting NSAID use, or metabolic syndrome limiting corticosteroid exposure, while Phase III data with formal hypothesis testing and longer follow-up are awaited before practice-changing adoption.